Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy
- Author(s)
- Thijssen, R; Tian, L; Anderson, MA; Flensburg, C; Jarratt, A; Garnham, AL; Jabbari, JS; Peng, H; Lew, TE; Teh, CE; Gouil, Q; Georgiou, A; Tan, T; Djajawi, TM; Tam, CS; Seymour, JF; Blombery, P; Gray, DHD; Majewski, IJ; Ritchie, ME; Roberts, AW; Huang, DCS;
- Details
- Publication Year 2022-11-17,Volume 140,Issue #20,Page 2127-2141
- Journal Title
- Blood
- Publication Type
- Research article
- Abstract
- Venetoclax (VEN) inhibits the prosurvival protein BCL2 to induce apoptosis and is a standard therapy for chronic lymphocytic leukemia (CLL), delivering high complete remission rates and prolonged progression-free survival in relapsed CLL but with eventual loss of efficacy. A spectrum of subclonal genetic changes associated with VEN resistance has now been described. To fully understand clinical resistance to VEN, we combined single-cell short- and long-read RNA-sequencing to reveal the previously unappreciated scale of genetic and epigenetic changes underpinning acquired VEN resistance. These appear to be multilayered. One layer comprises changes in the BCL2 family of apoptosis regulators, especially the prosurvival family members. This includes previously described mutations in BCL2 and amplification of the MCL1 gene but is heterogeneous across and within individual patient leukemias. Changes in the proapoptotic genes are notably uncommon, except for single cases with subclonal losses of BAX or NOXA. Much more prominent was universal MCL1 gene upregulation. This was driven by an overlying layer of emergent NF-kappaB (nuclear factor kappa B) activation, which persisted in circulating cells during VEN therapy. We discovered that MCL1 could be a direct transcriptional target of NF-kappaB. Both the switch to alternative prosurvival factors and NF-kappaB activation largely dissipate following VEN discontinuation. Our studies reveal the extent of plasticity of CLL cells in their ability to evade VEN-induced apoptosis. Importantly, these findings pinpoint new approaches to circumvent VEN resistance and provide a specific biological justification for the strategy of VEN discontinuation once a maximal response is achieved rather than maintaining long-term selective pressure with the drug.
- Keywords
- Humans; *Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy/genetics/metabolism; Myeloid Cell Leukemia Sequence 1 Protein/metabolism; Proto-Oncogene Proteins c-bcl-2/metabolism; NF-kappa B; Drug Resistance, Neoplasm/genetics; Bridged Bicyclo Compounds, Heterocyclic/pharmacology/therapeutic use; Recurrence; *Antineoplastic Agents/therapeutic use
- Department(s)
- Haematology; Pathology
- PubMed ID
- 35709339
- Publisher's Version
- https://doi.org/10.1182/blood.2022016040
- Open Access at Publisher's Site
https://doi.org/10.1182/blood.2022016040- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-04-17 07:51:24
Last Modified: 2025-04-17 07:51:48